Actinobacillus pleuropneumoniae 1型菌経鼻感染豚における呼吸器病変の免疫組織学的評価

書誌事項

タイトル別名
  • Immunohistological Evaluation on Respiratory Lesions of Pigs Intranasally Inoculated with Actinobacillus pleuropneumoniae Serotype 1.
  • Immunohistological evaluation on respir

この論文をさがす

抄録

Nine-week-old pigs were inoculated intranasally with 6.10×103 (group 103), 105 (group 105) and 107 (group 107) colony-forming unit of Actinobacillus pleuropneumoniae (App) serotype 1 designated HA-337 strain, respectively. One pig in group 105 and 2 pigs in group 107 died with dispnea and hemorrhagic pleuropneumonia within 20 to 48 hr post inoculation (PI). All pigs necropsied on 7 days in groups 105 and 107 had focal fibrous pleuropneumonia. Histologically, pulmonary lesions were classified into three stages; peracute, acute and subacute. Fatal cases in group 107 had peracute lesion composed of severe edema, hemorrhage and necrobiosis of alveoli, with mononuclear cells infiltration in the dilated interlobulus. The fatal case in group 105 had acute pulmonary lesion composed of focal or linear infiltration of round and fusiform cells that frequently showed swirling pattern in alveoli. The surviving cases in group 105 and 107 had subacute lesion composed of multifocal pulmonary necrosis surrounded by fibrous tissue. The swirling pattern was clearly seen in demarcation zone. Immunohistochemically, App antigens scattered as intact bacteria in alveoli, dilated interlobular septa and pleura, and lymph vessels in peracute and acute lesions. Areas of necrosis were also stained weakly. Although no antigen was detected in cytoplasm of macrophages and infiltrated cells in peracute lesions, App antigen was detected as positively stained mass in cytoplasm of some macrophages in acute lesions. In subacute lesions, App antigens were recognized as intact bacteria in necrotic areas and among the swirling pattern cells of demarcation zone. Macrophages had App antigens as a large mass of pigment in the cytoplasm in area of fibrosis.

収録刊行物

参考文献 (29)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ